Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib

SIMPLE SUMMARY: Osimertinib, a third-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has shown marked clinical benefit for non-small cell lung cancer (NSCLC) patients with EGFR activating mutations. However, resistance to osimertinib inevitably develo...

Descripción completa

Detalles Bibliográficos
Autores principales: La Monica, Silvia, Fumarola, Claudia, Cretella, Daniele, Bonelli, Mara, Minari, Roberta, Cavazzoni, Andrea, Digiacomo, Graziana, Galetti, Maricla, Volta, Francesco, Mancini, Maicol, Petronini, Pier Giorgio, Tiseo, Marcello, Alfieri, Roberta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792603/
https://www.ncbi.nlm.nih.gov/pubmed/33374971
http://dx.doi.org/10.3390/cancers13010006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792603/
https://www.ncbi.nlm.nih.gov/pubmed/33374971
http://dx.doi.org/10.3390/cancers13010006

Ejemplares similares